focus -WSS

focus

author：focus 2025-09-30 00:47:25 - browse：138

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

focus

WSS

Senators start work on Medicare physician payment reform

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Private equity deals in Medicare Advantage declines

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

For Medicare Advantage, Democrats want stronger protections around AI

Abortion pill case raises question: who can sue the FDA?

hotspot

focus

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Vaccine advisory panel ACIP left half staffed by HHS

Trump demands the U.S. pay no more for drugs than other countries … again

KalVista pill reduced swelling 'attacks' caused by genetic disease

Heart attack and stroke risk calculators need revising

PhRMA lawsuit over Medicare drug price negotiation tossed

In age of alternative facts, a scholarly course on calling out crap

Medicare Advantage proposed rates disappoint insurers

Medicare details structure of new drug price negotiation program

Vaccine advisory panel ACIP left half staffed by HHS

hotspot

Medicare threatens to cut off funding for HCA's Mission hospital

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

States should stop sabotaging methadone treatment reform

Abortion pill case raises question: who can sue the FDA?

Readout Newsletter: Merck, Vertex, and Viking updates

Supreme Court mifepristone arguments center on docs' right to sue

focus

explore

Wikipedia

knowledge